ClearPoint Neuro (CLPT) Competitors

$14.89 -0.26 (-1.71%)

As of 01:02 PM Eastern

CLPT vs. BFLY, NVCR, PLSE, EYE, and KMTS

Should you buy ClearPoint Neuro stock or one of its competitors? MarketBeat compares ClearPoint Neuro with other companies and stocks that may be similar based on industry, sector, market capitalization, business model, investor interest, or shared news coverage. Companies and stocks commonly compared with ClearPoint Neuro include Butterfly Network (BFLY), NovoCure (NVCR), Pulse Biosciences (PLSE), National Vision (EYE), and Kestra Medical Technologies (KMTS). These companies are all part of the "medical equipment" industry.

How does ClearPoint Neuro compare to Butterfly Network?

ClearPoint Neuro (NASDAQ:CLPT) and Butterfly Network (NYSE:BFLY) are both small-cap medical companies, but which is the superior business? We will contrast the two businesses based on the strength of their earnings, risk, valuation, dividends, institutional ownership, profitability, analyst recommendations and media sentiment.

In the previous week, Butterfly Network had 2 more articles in the media than ClearPoint Neuro. MarketBeat recorded 2 mentions for Butterfly Network and 0 mentions for ClearPoint Neuro. ClearPoint Neuro's average media sentiment score of 0.00 equaled Butterfly Network'saverage media sentiment score.

Company	Overall Sentiment
ClearPoint Neuro	Neutral
Butterfly Network	Neutral

ClearPoint Neuro currently has a consensus price target of $23.00, suggesting a potential upside of 54.46%. Butterfly Network has a consensus price target of $5.56, suggesting a potential downside of 15.02%. Given ClearPoint Neuro's higher probable upside, analysts clearly believe ClearPoint Neuro is more favorable than Butterfly Network.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
ClearPoint Neuro	1 Sell rating(s)	0 Hold rating(s)	2 Buy rating(s)	0 Strong Buy rating(s)	2.33
Butterfly Network	1 Sell rating(s)	2 Hold rating(s)	3 Buy rating(s)	0 Strong Buy rating(s)	2.33

ClearPoint Neuro has a beta of 1.23, meaning that its share price is 23% more volatile than the broader market. Comparatively, Butterfly Network has a beta of 2.05, meaning that its share price is 105% more volatile than the broader market.

30.1% of ClearPoint Neuro shares are held by institutional investors. Comparatively, 37.9% of Butterfly Network shares are held by institutional investors. 6.9% of ClearPoint Neuro shares are held by company insiders. Comparatively, 22.0% of Butterfly Network shares are held by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock will outperform the market over the long term.

ClearPoint Neuro has a net margin of -71.57% compared to Butterfly Network's net margin of -73.63%. Butterfly Network's return on equity of -34.41% beat ClearPoint Neuro's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
ClearPoint Neuro	-71.57%	-140.96%	-36.98%
Butterfly Network	-73.63%	-34.41%	-23.91%

ClearPoint Neuro has higher earnings, but lower revenue than Butterfly Network. Butterfly Network is trading at a lower price-to-earnings ratio than ClearPoint Neuro, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
ClearPoint Neuro	$36.97M	12.08	-$25.54M	-$1.01	N/A
Butterfly Network	$97.61M	17.08	-$77.06M	-$0.30	N/A

Summary

Butterfly Network beats ClearPoint Neuro on 10 of the 14 factors compared between the two stocks.

How does ClearPoint Neuro compare to NovoCure?

ClearPoint Neuro (NASDAQ:CLPT) and NovoCure (NASDAQ:NVCR) are both small-cap medical companies, but which is the better investment? We will compare the two businesses based on the strength of their analyst recommendations, risk, dividends, profitability, earnings, institutional ownership, media sentiment and valuation.

ClearPoint Neuro has higher earnings, but lower revenue than NovoCure. ClearPoint Neuro is trading at a lower price-to-earnings ratio than NovoCure, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
ClearPoint Neuro	$36.97M	12.08	-$25.54M	-$1.01	N/A
NovoCure	$655.35M	2.82	-$136.23M	-$1.53	N/A

NovoCure has a net margin of -25.66% compared to ClearPoint Neuro's net margin of -71.57%. NovoCure's return on equity of -50.82% beat ClearPoint Neuro's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
ClearPoint Neuro	-71.57%	-140.96%	-36.98%
NovoCure	-25.66%	-50.82%	-16.48%

ClearPoint Neuro presently has a consensus target price of $23.00, suggesting a potential upside of 54.46%. NovoCure has a consensus target price of $23.60, suggesting a potential upside of 47.93%. Given ClearPoint Neuro's stronger consensus rating and higher possible upside, equities research analysts plainly believe ClearPoint Neuro is more favorable than NovoCure.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
ClearPoint Neuro	1 Sell rating(s)	0 Hold rating(s)	2 Buy rating(s)	0 Strong Buy rating(s)	2.33
NovoCure	2 Sell rating(s)	3 Hold rating(s)	2 Buy rating(s)	0 Strong Buy rating(s)	2.00

ClearPoint Neuro has a beta of 1.23, meaning that its share price is 23% more volatile than the broader market. Comparatively, NovoCure has a beta of 0.94, meaning that its share price is 6% less volatile than the broader market.

In the previous week, NovoCure had 5 more articles in the media than ClearPoint Neuro. MarketBeat recorded 5 mentions for NovoCure and 0 mentions for ClearPoint Neuro. ClearPoint Neuro's average media sentiment score of 0.00 beat NovoCure's score of -0.01 indicating that ClearPoint Neuro is being referred to more favorably in the media.

Company	Overall Sentiment
ClearPoint Neuro	Neutral
NovoCure	Neutral

30.1% of ClearPoint Neuro shares are owned by institutional investors. Comparatively, 84.6% of NovoCure shares are owned by institutional investors. 6.9% of ClearPoint Neuro shares are owned by insiders. Comparatively, 5.5% of NovoCure shares are owned by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company will outperform the market over the long term.

Summary

ClearPoint Neuro beats NovoCure on 8 of the 15 factors compared between the two stocks.

How does ClearPoint Neuro compare to Pulse Biosciences?

ClearPoint Neuro (NASDAQ:CLPT) and Pulse Biosciences (NASDAQ:PLSE) are both small-cap medical companies, but which is the better business? We will contrast the two businesses based on the strength of their earnings, risk, dividends, institutional ownership, profitability, valuation, analyst recommendations and media sentiment.

30.1% of ClearPoint Neuro shares are held by institutional investors. Comparatively, 77.0% of Pulse Biosciences shares are held by institutional investors. 6.9% of ClearPoint Neuro shares are held by company insiders. Comparatively, 74.0% of Pulse Biosciences shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock will outperform the market over the long term.

Pulse Biosciences has a net margin of 0.00% compared to ClearPoint Neuro's net margin of -71.57%. Pulse Biosciences' return on equity of -86.67% beat ClearPoint Neuro's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
ClearPoint Neuro	-71.57%	-140.96%	-36.98%
Pulse Biosciences	N/A	-86.67%	-73.61%

ClearPoint Neuro currently has a consensus price target of $23.00, suggesting a potential upside of 54.46%. Pulse Biosciences has a consensus price target of $30.67, suggesting a potential upside of 9.19%. Given ClearPoint Neuro's higher probable upside, equities research analysts plainly believe ClearPoint Neuro is more favorable than Pulse Biosciences.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
ClearPoint Neuro	1 Sell rating(s)	0 Hold rating(s)	2 Buy rating(s)	0 Strong Buy rating(s)	2.33
Pulse Biosciences	1 Sell rating(s)	0 Hold rating(s)	3 Buy rating(s)	0 Strong Buy rating(s)	2.50

ClearPoint Neuro has higher revenue and earnings than Pulse Biosciences. Pulse Biosciences is trading at a lower price-to-earnings ratio than ClearPoint Neuro, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
ClearPoint Neuro	$36.97M	12.08	-$25.54M	-$1.01	N/A
Pulse Biosciences	$350K	5,553.61	-$72.78M	-$1.10	N/A

In the previous week, Pulse Biosciences had 1 more articles in the media than ClearPoint Neuro. MarketBeat recorded 1 mentions for Pulse Biosciences and 0 mentions for ClearPoint Neuro. Pulse Biosciences' average media sentiment score of 0.59 beat ClearPoint Neuro's score of 0.00 indicating that Pulse Biosciences is being referred to more favorably in the news media.

Company	Overall Sentiment
ClearPoint Neuro	Neutral
Pulse Biosciences	Positive

ClearPoint Neuro has a beta of 1.23, indicating that its stock price is 23% more volatile than the broader market. Comparatively, Pulse Biosciences has a beta of 1.65, indicating that its stock price is 65% more volatile than the broader market.

Summary

Pulse Biosciences beats ClearPoint Neuro on 10 of the 16 factors compared between the two stocks.

How does ClearPoint Neuro compare to National Vision?

ClearPoint Neuro (NASDAQ:CLPT) and National Vision (NASDAQ:EYE) are both small-cap medical equipment companies, but which is the better investment? We will contrast the two companies based on the strength of their earnings, valuation, profitability, media sentiment, institutional ownership, analyst recommendations, dividends and risk.

ClearPoint Neuro presently has a consensus price target of $23.00, indicating a potential upside of 54.46%. National Vision has a consensus price target of $30.08, indicating a potential upside of 49.33%. Given ClearPoint Neuro's higher probable upside, research analysts plainly believe ClearPoint Neuro is more favorable than National Vision.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
ClearPoint Neuro	1 Sell rating(s)	0 Hold rating(s)	2 Buy rating(s)	0 Strong Buy rating(s)	2.33
National Vision	0 Sell rating(s)	5 Hold rating(s)	7 Buy rating(s)	0 Strong Buy rating(s)	2.58

National Vision has a net margin of 2.31% compared to ClearPoint Neuro's net margin of -71.57%. National Vision's return on equity of 6.41% beat ClearPoint Neuro's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
ClearPoint Neuro	-71.57%	-140.96%	-36.98%
National Vision	2.31%	6.41%	2.81%

National Vision has higher revenue and earnings than ClearPoint Neuro. ClearPoint Neuro is trading at a lower price-to-earnings ratio than National Vision, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
ClearPoint Neuro	$36.97M	12.08	-$25.54M	-$1.01	N/A
National Vision	$1.99B	0.81	$29.60M	$0.57	35.34

30.1% of ClearPoint Neuro shares are owned by institutional investors. 6.9% of ClearPoint Neuro shares are owned by company insiders. Comparatively, 2.4% of National Vision shares are owned by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company is poised for long-term growth.

In the previous week, National Vision had 2 more articles in the media than ClearPoint Neuro. MarketBeat recorded 2 mentions for National Vision and 0 mentions for ClearPoint Neuro. National Vision's average media sentiment score of 1.77 beat ClearPoint Neuro's score of 0.00 indicating that National Vision is being referred to more favorably in the news media.

Company	Overall Sentiment
ClearPoint Neuro	Neutral
National Vision	Very Positive

ClearPoint Neuro has a beta of 1.23, indicating that its share price is 23% more volatile than the broader market. Comparatively, National Vision has a beta of 1.04, indicating that its share price is 4% more volatile than the broader market.

Summary

National Vision beats ClearPoint Neuro on 11 of the 16 factors compared between the two stocks.

How does ClearPoint Neuro compare to Kestra Medical Technologies?

Kestra Medical Technologies (NASDAQ:KMTS) and ClearPoint Neuro (NASDAQ:CLPT) are both small-cap medical companies, but which is the better stock? We will contrast the two companies based on the strength of their earnings, profitability, institutional ownership, analyst recommendations, valuation, dividends, media sentiment and risk.

Kestra Medical Technologies currently has a consensus target price of $27.83, indicating a potential upside of 18.52%. ClearPoint Neuro has a consensus target price of $23.00, indicating a potential upside of 54.46%. Given ClearPoint Neuro's higher probable upside, analysts clearly believe ClearPoint Neuro is more favorable than Kestra Medical Technologies.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Kestra Medical Technologies	1 Sell rating(s)	1 Hold rating(s)	3 Buy rating(s)	0 Strong Buy rating(s)	2.40
ClearPoint Neuro	1 Sell rating(s)	0 Hold rating(s)	2 Buy rating(s)	0 Strong Buy rating(s)	2.33

30.1% of ClearPoint Neuro shares are owned by institutional investors. 3.6% of Kestra Medical Technologies shares are owned by insiders. Comparatively, 6.9% of ClearPoint Neuro shares are owned by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock is poised for long-term growth.

In the previous week, Kestra Medical Technologies had 21 more articles in the media than ClearPoint Neuro. MarketBeat recorded 21 mentions for Kestra Medical Technologies and 0 mentions for ClearPoint Neuro. ClearPoint Neuro's average media sentiment score of 0.00 beat Kestra Medical Technologies' score of -0.02 indicating that ClearPoint Neuro is being referred to more favorably in the news media.

Company	Overall Sentiment
Kestra Medical Technologies	Neutral
ClearPoint Neuro	Neutral

ClearPoint Neuro has a net margin of -71.57% compared to Kestra Medical Technologies' net margin of -138.35%. Kestra Medical Technologies' return on equity of -57.38% beat ClearPoint Neuro's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Kestra Medical Technologies	-138.35%	-57.38%	-41.10%
ClearPoint Neuro	-71.57%	-140.96%	-36.98%

Kestra Medical Technologies has a beta of 0.47, indicating that its stock price is 53% less volatile than the broader market. Comparatively, ClearPoint Neuro has a beta of 1.23, indicating that its stock price is 23% more volatile than the broader market.

ClearPoint Neuro has lower revenue, but higher earnings than Kestra Medical Technologies. ClearPoint Neuro is trading at a lower price-to-earnings ratio than Kestra Medical Technologies, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Kestra Medical Technologies	$95.13M	14.47	-$131.61M	-$2.42	N/A
ClearPoint Neuro	$36.97M	12.08	-$25.54M	-$1.01	N/A

Summary

ClearPoint Neuro beats Kestra Medical Technologies on 9 of the 16 factors compared between the two stocks.

Get ClearPoint Neuro News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding CLPT and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

CLPT vs. The Competition

Export

Metric	ClearPoint Neuro	MED INSTRUMENTS Industry	Medical Sector	NASDAQ Exchange
Market Cap	$446.67M	$7.26B	$6.82B	$12.36B
Dividend Yield	N/A	1.32%	2.67%	9.36%
P/E Ratio	-14.75	49.62	27.16	24.05
Price / Sales	12.08	81.53	573.09	112.68
Price / Cash	N/A	26.91	29.05	48.09
Price / Book	15.04	6.97	10.68	6.18
Net Income	-$25.54M	$162.27M	$3.59B	$331.63M
7 Day Performance	-9.81%	-1.67%	-1.56%	-1.49%
1 Month Performance	-16.20%	-1.33%	1.10%	-1.21%
1 Year Performance	35.00%	7.29%	24.47%	17.67%

ClearPoint Neuro Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
CLPT ClearPoint Neuro	2.7794 of 5 stars	$14.89 -1.7%	$23.00 +54.5%	+37.4%	$446.67M	$36.97M	N/A	110	Analyst Forecast
BFLY Butterfly Network	0.8878 of 5 stars	$8.09 +1.3%	$5.56 -31.2%	+255.9%	$2.03B	$97.61M	N/A	460
NVCR NovoCure	2.5176 of 5 stars	$16.09 -1.3%	$23.60 +46.7%	-0.6%	$1.89B	$655.35M	N/A	1,605	Upcoming Earnings
PLSE Pulse Biosciences	1.7097 of 5 stars	$25.89 -1.5%	$30.67 +18.4%	+89.9%	$1.82B	$350K	N/A	140
EYE National Vision	3.9716 of 5 stars	$19.29 -1.3%	$30.08 +56.0%	-17.4%	$1.57B	$1.99B	33.84	13,138	News Coverage Positive News

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:CLPT) was last updated on 7/20/2026 by MarketBeat.com Staff.

From Our Partners

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

ClearPoint Neuro (CLPT) Competitors

CLPT vs. BFLY, NVCR, PLSE, EYE, and KMTS

How does ClearPoint Neuro compare to Butterfly Network?

Summary

How does ClearPoint Neuro compare to NovoCure?

Summary

How does ClearPoint Neuro compare to Pulse Biosciences?

Summary

How does ClearPoint Neuro compare to National Vision?

Summary

How does ClearPoint Neuro compare to Kestra Medical Technologies?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

CLPT vs. The Competition

ClearPoint Neuro Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

ClearPoint Neuro (CLPT) Competitors

CLPT vs. BFLY, NVCR, PLSE, EYE, and KMTS

How does ClearPoint Neuro compare to Butterfly Network?

Does the media favor CLPT or BFLY?

Do analysts recommend CLPT or BFLY?

Which has more risk & volatility, CLPT or BFLY?

Do institutionals and insiders hold more shares of CLPT or BFLY?

Is CLPT or BFLY more profitable?

Which has preferable valuation and earnings, CLPT or BFLY?

Summary

How does ClearPoint Neuro compare to NovoCure?

Which has better valuation and earnings, CLPT or NVCR?

Is CLPT or NVCR more profitable?

Do analysts prefer CLPT or NVCR?

Which has more volatility and risk, CLPT or NVCR?

Does the media refer more to CLPT or NVCR?

Do institutionals & insiders hold more shares of CLPT or NVCR?

Summary

How does ClearPoint Neuro compare to Pulse Biosciences?

Do insiders & institutionals hold more shares of CLPT or PLSE?

Is CLPT or PLSE more profitable?

Do analysts recommend CLPT or PLSE?

Which has better earnings and valuation, CLPT or PLSE?

Does the media refer more to CLPT or PLSE?

Which has more risk and volatility, CLPT or PLSE?

Summary

How does ClearPoint Neuro compare to National Vision?

Do analysts recommend CLPT or EYE?

Is CLPT or EYE more profitable?

Which has preferable valuation & earnings, CLPT or EYE?

Do institutionals & insiders believe in CLPT or EYE?

Does the media refer more to CLPT or EYE?

Which has more volatility & risk, CLPT or EYE?

Summary

How does ClearPoint Neuro compare to Kestra Medical Technologies?

Do analysts prefer KMTS or CLPT?

Do insiders & institutionals believe in KMTS or CLPT?

Does the media refer more to KMTS or CLPT?

Is KMTS or CLPT more profitable?

Which has more risk and volatility, KMTS or CLPT?

Which has stronger valuation and earnings, KMTS or CLPT?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

CLPT vs. The Competition

ClearPoint Neuro Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools